Latest News

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results

CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)–<a href="" target="_blank">$KALV</a>–KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors today provided an operational update and released financial results for the fiscal year ended April 30, 2019. “This fiscal year has been busy as we prepare for data in two Phase 2 clinical trials before the end of 2019,” said Andrew Crockett, Chief Executiv

Source link

Related posts

Seven key heart health measures may help predict future risk of CVD


U.S. ERs See Doubling of Teen Sexual Abuse Cases


Medical News Today: Can scientists learn to bypass superbugs' drug resistance?


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy